2022 Annual Meeting | C48 - Blockbuster or Bankrupt: A Debate on When to Use New Drugs

Date Sunday 04/03/22

Time 01:00 PM - 03:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Kavita Nair, PhD, FAAN

Topic(s) Practice, Policy, and Ethics

Learning Objectives The high cost of newer, innovative medications to treat neurological disease has created both excitement and challenges for all stakeholders in the US healthcare systems. Availability of costly FDA approved therapies for the treatment of the rare disease AQP4 +neuromyelitis optica spectrum disorder (NMOSD) or for the more prevalent disease migraine poses challenges for neurologists as they assess the value in using these therapies. Through presentations from the Institute of Clinical and Economic Review (ICER), neurology specific compiled from AAN and debates with leading clinical experts in these disease areas, faculty will facilitate an understanding of value assessment in using high cost drugs.Participants will learn the principles of value assessment regarding high priced medications as defined by the Institute of Clinical and Economic Review’s framework.Participants will be presented with data regarding the impact of high priced neurology drugs on outcomes of care.Participants will appraise two pro/con debates with leading clinical experts regarding the use of high priced drugs in AQP4 +neuromyelitis optica spectrum disorder (NMOSD) and migraine.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM PDT	Introduction	Introduction Kavita Nair, PhD, FAAN
01:00 PM - 01:00 PM PDT	Speaker	walk in slides Kavita Nair, PhD, FAAN
01:05 PM - 01:30 PM PDT	Speaker	Value Assessment of High Cost Drugs in Neurology- the ICER Perspective Jonathan D. Campbell, PhD
01:30 PM - 01:50 PM PDT	Speaker	The Price of High Cost Drugs in Neurology Brian Callaghan, MD, MS, FAAN
01:50 PM - 02:20 PM PDT	Speaker	Pro/Con Debate: When to Use High Cost Drugs for NMOSD Jeffrey L. Bennett, MD, PhD, FAAN, Stacey Clardy, MD, PhD, FAAN
02:20 PM - 02:45 PM PDT	Speaker	Pro/Con Debate: When to Use High Cost Drugs for Migraine Amanda E. Macone, MD, Elizabeth Loder, MD, FACP
02:45 PM - 03:00 PM PDT	Q&A	Questions and Answers Kavita Nair, PhD, FAAN, Brad C. Klein, MD, MBA, FAAN

Faculty Disclosures
Kavita Nair, PhD, FAAN	Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PhRMA Foundation. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MJH Healthcare. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anylam . Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi-Genzyme. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Phrma Foundation. The institution of Dr. Nair has received research support from Bristol Meyers Squibb. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from NINDS.
Brian Callaghan, MD, MS, FAAN	Dr. Callaghan has received personal compensation for serving as an employee of University of Michigan. Dr. Callaghan has received personal compensation for serving as an employee of Ann Arbor Veterans Affairs. Dr. Callaghan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dynamed. Dr. Callaghan has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. Dr. Callaghan has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Medico-legal work. Dr. Callaghan has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Vaccine Injury Compensation Program. The institution of Dr. Callaghan has received research support from American Academy of Neurology. The institution of Dr. Callaghan has received research support from JDRF. The institution of Dr. Callaghan has received research support from NIDDK. Dr. Callaghan has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with NIH.
Jeffrey L. Bennett, MD, PhD, FAAN	Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon Therapeutics. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Bennett has received personal compensation in the range of $0-$499 for serving as a Consultant for Genentech. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chugai. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ImCyse. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Beigene. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Pavich. The institution of Dr. Bennett has received research support from Alexion. Dr. Bennett has received intellectual property interests from a discovery or technology relating to health care. Dr. Bennett has received publishing royalties from a publication relating to health care.
Amanda E. Macone, MD	Dr. Macone has nothing to disclose.
Elizabeth Loder, MD, FACP	Dr. Loder has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of New England. The institution of Dr. Loder has received personal compensation in the range of $100,000-$499,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The BMJ. Dr. Loder has received publishing royalties from a publication relating to health care.
Brad C. Klein, MD, MBA, FAAN	Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly and Company. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. Klein has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for AbbVie. Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly and Company. Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Impel. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biodelivery Science. The institution of Dr. Klein has received research support from AbbVie. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Shareholder with AppsbyDocs, LLC. Dr. Klein has a non-compensated relationship as a Chair, Practice Management Committee with American Headache Society that is relevant to AAN interests or activities.
Stacey Clardy, MD, PhD, FAAN	Dr. Clardy has received personal compensation for serving as an employee of Veterans Health Administration (VHA). Dr. Clardy has received personal compensation for serving as an employee of University of Utah Health. Dr. Clardy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca/Alexion. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen/Horizon. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna. Dr. Clardy has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology/AAN Publications. The institution of Dr. Clardy has received research support from NIH/NINDS. The institution of Dr. Clardy has received research support from SRNA. The institution of Dr. Clardy has received research support from Alexion/AstraZeneca. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a AAN Summer Meeting CoDirector Travel and Lodging with AAN. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a Grand Rounds Travel/Lodging/Honoraria with U of Iowa, Miami, Stanford, Barrow, Beaumont Health, CCF, Emory, Penn State, Mayo Clinic, Walter Reed.
Jonathan D. Campbell, PhD	Dr. Campbell has received personal compensation for serving as an employee of Institute for Clinical and Economic Review.